Actinogen Medical Appoints Dr Geoff Brooke as Chairman

Actinogen Medical is pleased to announce that is has appointed healthcare industry and venture capital veteran, Dr Geoff Brooke, as Chairman, effective 1^st March.

KEY TAKEAWAYS:

• Appointed of healthcare industry and venture capital veteran, Dr Geoff Brooke, as new Chairman.
• Adds significant life sciences and financial expertise to the Actinogen Board, with Dr Brooke having 30 years’ international experience as the founder, lead investor and Chairman/Director of numerous healthcare companies.
• Dr Brooke was Managing Director and Founder of leading life sciences venture capital firm, GBS Ventures is a Non-Executive Director of ASX-listed company, Acrux Limited (ASX: ACR).
• Dr Brooke’s experience will be invaluable as Actinogen begins patient recruitment in their XanADu Phase II Alzheimer’s trial in early Q2 2017 and progresses through to study completion and data read-out in early 2019.

Dr Brooke was also President and Founder of US-based seed healthcare venture capital firm, Medvest Inc, with investors including the venture capital arm of leading global multinational medical devices, pharmaceutical and consumer packaged goods manufacturer, Johnson & Johnson. Medvest was focused on founding companies based upon health care-related technology, including pharmaceuticals, biotechnology, therapeutic devices, medical services and information systems.

Dr Brooke now acts a private investor in, and independent director for, a number of small to medium-sized Australian and US private and public companies, including Non-Executive Director for ASX-listed company, Acrux Limited (ASX:ACR).

He holds a Bachelor of Medicine and a Bachelor of Surgery from Melbourne University and a Masters of Business Administration from IMEDE Switzerland (now IMD).

“We are thrilled to have someone of Geoff’s calibre joining Actinogen as Chairman. Geoff brings a wealth of expertise across the Australian and US listed healthcare space and in-depth knowledge of all aspects of financing healthcare and life sciences companies,” said Dr Bill Ketelbey, CEO of Actinogen Medical.

“His knowledge will be invaluable as we progress through to study completion and data read-out of our XanADu Phase II clinical trial – the largest global Alzheimer’s dementia study conducted by an Australian biotech company – which is on target to treat first patients with Xanamem™ in early Q2 2017.”

Request Information